Textbooks
A Handbook of Vascular Disease Management By Wesley S. Moore, Juan Carlos Jimenez - World Scientific Pub Co Inc (2011)Treatment of vascular disease has progressed and evolved rather quickly in the last 5–10 years with current treatments improving and changing rapidly. This handbook serves to educate medical students and surgery residents regarding the most up-to-date treatments for arterial, venous and lymphatic disease. Endovascular management of these disorders has emerged rapidly and the most current techniques will be covered in detail.
Professor and Chief, Emeritus
Division of Vascular Surgery
UCLA Medical Center
Practice limited to treatment of carotid artery disease and aortic aneurysm including the less invasive stent-graft repair.
ENDOVASCULAR GRAFT CURRENT CLINICAL TRIALS
I am pleased to announce that UCLA Medical Center will be involved in a clinical trial designed to evaluate the safety and efficacy of a new generation of endovascular graft designed to treat abdominal aortic aneurysm.
We have been offering a less-invasive approach for the management of patients with abdominal aortic aneurysm using endovascular technology(EVAR) since the introduction of the first commercially manufactured device in 1993. As device technology has improved, we have been gradually able to offer a larger percentage of patients with abdominal aortic aneurysm less invasive management. This has resulted in shorter hospital stays and rapid recovery. At the present time, approximately 60-70% of patients that I see with abdominal aortic aneurysm are candidates for currently available devices. The remainder are not candidates for EVAR and require conventional open repair, usually because of anatomic limitations. A new device, offered by TriVascular, has the potential for greatly expanding the population of patients that will be candidate for endovascular repair. Because of some unique engineering features of the new device, we can now offer endovascular repair of abdominal aortic aneurysm to patients with a relatively short distance between the renal arteries and the beginning of the aneurysm sac as well as patients who have small iliac arteries. The new device has a very low profile delivery system as well as a technique for obtaining a better seal and longitudinal stability that may reduce endoleak and permits us to offer endovascular repair to patients who would have been previously turned down because they do not meet the anatomic requirements for currently commercially available devices.
If you have a patient who you would like us to consider for the new device, please contact our Clinical Studies Coordinator, Kathleen Land, RN, at (310) 206-1115, or you may contact my office directly. Of course, we will provide appropriate feedback to you regarding your patient’s eligibility as well as outcome should they decide to participate in the trial.